Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

Abstract

Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective firstline therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt’s lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.